Private Equity Veterinary Medicine: Top Firms in 2026

Key Facts

• Over 20 active PE-backed platforms and 35+ total corporate consolidators operate in the veterinary sector as of 2026.
• Private equity firms deployed $51.6 billion into veterinary practices from 2017 to 2023, plus $9.3 billion in the first four months of 2024 alone.
• Corporate owners control approximately 25-30% of general veterinary practices, up from 8-10% a decade ago. Corporate operators already own 75% of specialty and emergency clinics.
• The dominant strategy is roll-up consolidation: buy independent practices at 5-7x earnings before interest, taxes, depreciation, and amortization (EBITDA), then sell a consolidated network at 12-15x EBITDA.
• Acquisition multiples ranged from 6x to 16x adjusted EBITDA in Q1 2025, depending on practice size, staff stability, and location.
• Rising interest rates since 2022 have slowed deal pace, but PE remains the largest buyer of veterinary clinics as of 2026.
• The FTC issued a consent decree against JAB Consumer Partners in 2022, requiring divestitures in California, Colorado, Texas, Virginia, and Washington D.C.

The Veterinary PE Market: Sector and Geographic Overview

Private equity in veterinary medicine centers on one core thesis: a fragmented market of independently owned clinics can be consolidated into regional and national chains, then sold at a premium multiple. Roughly 30,000 veterinary clinics operate across the United States. The majority remain independently owned, providing a long runway for further consolidation. The pandemic accelerated this trend sharply, with the pet ownership boom of 2020-2022 driving elevated demand that made the sector look recession-proof to fund managers seeking stable cash flows.

The cash-pay model is the defining structural advantage attracting PE investors. Unlike human healthcare, veterinary services bypass third-party insurers entirely, delivering direct cash flow that services acquisition debt more reliably. Practices collect all revenue at point of service, with pet insurance uptake still in the low single digits. Americans spent an estimated $38 billion on companion animal healthcare in 2023, up from $29 billion in 2019.

Corporate consolidation spans the country, with no single dominant hub. The FTC's 2022 action against JAB specifically targeted California, Colorado, Texas, Virginia, and Washington D.C. as markets where concentration had reached anticompetitive levels. New York hosts active platforms including Bond Vet (50 urban locations) and Thrive's Rochester presence. Iowa, Alabama, and the Pacific Northwest also show active consolidation activity. Eighteen states currently restrict non-veterinarian ownership, creating legal complexity that PE firms frequently navigate through management services organization (MSO) structures.

Veterinary PE Consolidators: Firm Comparison

The table below covers the largest PE-backed platforms by practice count, based on data current through early 2026. Platform entity AUM figures remain undisclosed; the KKR figure reflects firm-wide assets under management.

KKR's backing of PetVet gives it the strongest institutional pedigree in this peer group. Shore Capital Partners stands out as the only PE firm running two major platforms simultaneously, with a combined 655 practices and a planned merger creating a 730-practice entity. VetCor, backed by Harvest Partners alongside Cressey & Co., has been the most acquisitive single platform over the past 24 months.

Top Picks by Investment Strategy

Largest Platform Operator (Corporate): Mars Inc. controls over 2,000 US veterinary practices through Banfield, VCA, and BluePearl. No PE firm matches its scale or geographic reach.

Most Active PE Roll-Up: VetCor (Harvest Partners) led all platforms in acquisition velocity over the 24 months through mid-2024, adding locations at a pace that outstripped peers with 917 total practices.

Mega-Fund Backing: KKR's sponsorship of PetVet Care Centers (456 practices) brings the deepest capital reserve and institutional resources of any PE sponsor in this niche. KKR manages over $500 billion firm-wide.

Dual-Platform Consolidator: Shore Capital Partners is the most strategically aggressive mid-market firm, running Southern Veterinary Partners and Mission Veterinary Partners simultaneously and engineering a merger into a combined 730-practice group.

Specialty and Emergency Leader: JAB Holding Company controls both NVA (1,013 practices) and Ethos Veterinary Health (154 specialty practices), giving it unmatched depth across both general and specialty care.

Urban Growth Equity Play: Warburg Pincus backs Bond Vet's 50-location urban model, the clearest example of growth equity applied to veterinary medicine in dense metropolitan markets.

Newest Platform Builders: Chicago Pacific Founders (Pieper Veterinary) and Varsity Healthcare Partners (VetEvolve) both launched new platforms in 2023-2024, signaling that uncommitted capital continues to chase fresh consolidation opportunities despite the broader slowdown.

Long-Hold Alternative: Lakefield Veterinary Group (74 practices), backed by the Demarais family and Peloton Capital, operates on a 10+ year hold model that differs structurally from standard PE exit timelines.

Leading Veterinary PE Platforms in Detail

KKR and PetVet Care Centers

The strongest institutional signal in veterinary PE belongs to KKR, the New York-based buyout firm managing over $500 billion in firm-wide assets. KKR's investment thesis on PetVet Care Centers (456 practices) mirrors its broader healthcare services strategy: capture economies of scale in purchasing, staffing, and technology through a scaled platform. PetVet's practice count places it third among PE-backed platforms, behind only NVA and VetCor. For limited partners building exposure to the animal health market, PetVet represents the clearest connection between a globally recognized general partner and veterinary roll-up economics.

JAB Holding Company: The Specialist Aggregator

JAB Consumer Partners has assembled the most concentrated veterinary portfolio of any single PE-style investor, combining NVA's 1,013 general and specialty practices with Ethos Veterinary Health's 154 specialty locations. The Luxembourg-based holding company extended its pet care investment thesis into pet insurance, acquiring multiple US and European brands. The FTC's 2022 consent decree required divestitures across five states. It also imposed a decade-long pre-approval requirement before JAB could purchase additional emergency or specialty clinics within 25 miles of existing holdings in California and Texas. NVA's planned initial public offering in 2025-2026 would mark one of the most significant exit events in veterinary PE history.

Harvest Partners and VetCor

VetCor's 917-practice network resulted from Harvest Partners' consistent buy-and-build execution, conducted alongside healthcare-specialist co-investor Cressey & Co. The platform's position as the most active consolidator over the 24 months preceding mid-2024 reflects a disciplined bolt-on acquisition strategy targeting general practices rather than specialty or emergency clinics. VetCor's scale gives it meaningful leverage in vendor negotiations and centralized administration, the two primary sources of EBITDA margin improvement in roll-up models. Practice owners evaluating general practice acquisition offers will frequently encounter VetCor as the most active bidder in their market.

Shore Capital Partners: The Dual-Platform Builder

Shore Capital Partners runs the most ambitious multi-platform strategy in veterinary medicine. Its Chicago-based team simultaneously built Southern Veterinary Partners (380 practices, focused on the South) and Mission Veterinary Partners (275 practices with a nationwide footprint), then announced a merger creating a 730-practice combined entity. No other PE sponsor in this niche has executed two parallel platforms and then engineered a portfolio company merger at this scale. Shore's human healthcare experience, spanning multiple physician group investments, provides an operational playbook that transfers directly to veterinary practice management.

TSG Consumer Partners and Thrive Pet Healthcare

Thrive Pet Healthcare's 369 practices reflect TSG Consumer Partners' consumer brand investment thesis applied to veterinary services. TSG's distinguishing feature within this peer group is an explicit policy of not rebranding acquired practices, preserving local identity to reduce client attrition post-acquisition. The strategy's limits emerged in Rochester, New York, where Thrive closed the metro area's only 24-hour emergency clinic in 2023, drawing significant community pushback. Thrive's Austin, Texas headquarters places it in a market where TSG maintains existing consumer sector relationships.

Warburg Pincus and Bond Vet

Bond Vet represents the clearest departure from the leveraged buyout model dominating veterinary PE. Warburg Pincus, one of the largest global growth equity investors, backs Bond Vet's 50-location urban network with a structure that prioritizes revenue growth over debt-financed acquisition volume. Bond Vet targets dense urban Northeast markets where high-income pet owners support premium pricing and multi-service appointments. This model provides an alternative proof of concept: veterinary consolidation does not require heavy leverage when unit economics support organic growth. Warburg's $73 billion in firm-wide assets under management gives Bond Vet access to capital that most specialist fund managers cannot match.

Audax Private Equity and Veterinary Practice Partners

Audax Private Equity's Boston-based team applies its established lower-middle-market buy-and-build playbook to Veterinary Practice Partners (approximately 175 practices). Audax has built multi-platform portfolios across healthcare, business services, and industrial sectors using the same bolt-on acquisition model. Veterinary Practice Partners' practice count makes it a mid-tier platform: large enough to achieve meaningful purchasing scale, but small enough that further bolt-on acquisitions can still move the needle on enterprise value. Practice owners considering a sale below the threshold that KKR or JAB typically target represent the natural acquisition pool for Audax's approach.

Nordic Capital and United Veterinary Care

Nordic Capital brings a European PE perspective to US veterinary consolidation through United Veterinary Care (104 practices). The Stockholm and New York-based firm has deep healthcare services experience across Scandinavia and the UK, where veterinary corporate ownership rates exceed even those in the United States. This cross-border operational knowledge informs how United Veterinary Care approaches practice integration, particularly around clinical protocol standardization and workforce management. Nordic's involvement signals that European PE capital actively competes with domestic US funds for veterinary deal flow.

Key Investment Trends in Animal Health Consolidation

Roll-Up Arbitrage and EBITDA Multiple Expansion

The foundational thesis in veterinary private equity depends on a simple multiple arbitrage. Sponsors acquire independent practices at 5-7x EBITDA, consolidate them into a regional or national network, then sell the platform at 12-15x EBITDA. Q1 2025 transaction data shows the range has widened to 6x-16x adjusted EBITDA depending on practice size, staff stability, and location. Top-performing locations in high-density markets command 15x or more. Rate-driven multiple compression beginning in 2022 has slowed new acquisitions, but the arbitrage logic remains intact for platforms assembled at lower borrowing costs.

Regulatory Friction and FTC Serial Acquisition Scrutiny

The FTC's December 2022 merger guidelines explicitly enable regulators to evaluate the cumulative impact of multiple smaller acquisitions, directly targeting the roll-up strategy driving veterinary PE. The JAB consent decree demonstrated that the agency will require divestitures when emergency and specialty market concentration crosses a threshold. Eighteen states currently ban non-veterinarian ownership outright, and PE firms navigate this through MSO structures that state legislatures increasingly target. The UK government launched a formal investigation into veterinary market concentration in 2024, potentially setting a regulatory precedent that accelerates US enforcement.

Specialty and Emergency Consolidation Approaching Saturation

Corporate and PE operators already own approximately 75% of specialty and emergency veterinary practices, compared to 25-30% of general practices. The remaining consolidation runway sits almost entirely in primary care, where practices typically command lower EBITDA multiples and require higher acquisition volume to build meaningful scale. New platforms created in 2023-2024, including Pieper Veterinary and VetEvolve, target general practice specifically. The specialty segment faces a different challenge: further consolidation will almost certainly trigger additional FTC scrutiny given existing concentration levels.

Adjacent Sector Expansion Beyond the Clinic

PE investment is flowing beyond the clinic into pet insurance, veterinary telemedicine, diagnostics, and pet sitting platforms. JAB acquired multiple US and European pet insurance brands as part of its broader pet care investment thesis. Blackstone acquired Rover, the largest US pet sitting and dog walking platform, in February 2024. Warburg Pincus-backed Bond Vet has explored telehealth adjacencies. These adjacent bets reflect PE sponsors seeking to capture a larger share of the $147 billion total US pet spending market rather than competing only for clinic acquisition targets.

Interest Rate Pressure on Leveraged Acquisition Models

Most veterinary platforms structured their acquisitions using variable-rate debt under assumptions of near-zero borrowing costs. Rising interest rates since 2022 have materially increased debt service costs, compressing the margins that make roll-up returns achievable. This pressure has two likely outcomes: some platforms will pursue accelerated exits through secondary buyouts or the IPO route (as NVA is pursuing), while distressed platforms may face clinic closures or forced sales. VetCor's continued aggressive acquisition pace despite rate headwinds suggests Harvest Partners judges that platform scale mitigates per-unit debt costs.

How to Evaluate Veterinary Private Equity Firms

Track record is the most reliable differentiator among veterinary PE sponsors. A firm's history of practice culture preservation, staff retention, and clinical autonomy post-acquisition matters more than its stated commitments. Ask for references from practice owners who sold to the same consolidator at least three years prior, not from recent transactions where integration has barely begun.

Deal structure determines long-term outcomes for practice owners. A typical transaction includes 70-90% upfront cash and 10-30% equity rollover into the consolidated platform. The equity rollover provides a "second bite" at exit. This only pays off when the exit multiple and timeline align with initial projections. High debt loads on the acquired practice entity itself reduce clinical reinvestment capacity and increase closure risk if the platform's financial performance deteriorates.

For LPs evaluating fund managers with veterinary exposure, the key metrics are exit multiples on completed secondary buyouts, not projected internal rates of return (IRRs) on current holdings. Most exits in this sector have been PE-to-PE secondary sales rather than strategic sales or IPOs. NVA's planned public offering would be the first major test of public market appetite for veterinary roll-up economics. Fund size and vintage matter: funds raised before 2020 at low leverage costs face different return dynamics than funds raised after the 2022 rate environment shift.

Single-doctor practices face increasing difficulty attracting PE acquisition bids. Multi-doctor practices with normalized EBITDA above $500,000 and established wellness plan revenues are the preferred acquisition target across platforms. Practice owners considering a sale should prepare clean financial records with normalized owner compensation and engage a specialized veterinary M&A broker to create competitive bidding rather than negotiating directly with any single platform's business development team.

Which Firm Fits Your Needs?

Practice owners seeking maximum upfront liquidity and brand continuity should evaluate VetCor, Thrive, and Shore Capital's platforms first. VetCor has demonstrated the highest acquisition velocity in the current market, suggesting active uncommitted capital. Thrive's documented non-rebranding policy addresses legacy concerns more directly than most competitors. Shore Capital's dual-platform structure creates internal competition for acquisition targets that can benefit sellers during negotiations.

LPs building diversified alternative asset exposure to the pet care market have clearest access through KKR's institutional fund vehicles, which include PetVet Care Centers as a healthcare services portfolio company. Warburg Pincus provides an alternative entry point with a growth equity structure rather than a leveraged buyout, reducing the interest rate sensitivity that has pressured debt-heavy competitors. Nordic Capital offers exposure to a European sponsor with genuine operational expertise in veterinary consolidation across multiple markets.

Veterinarians employed at or considering joining corporate practices will encounter meaningful differences among platforms. A national veterinary medicine survey found 55.1% of surveyed veterinarians preferred independent practice environments. Corporate practices reported significantly higher pressure to see more clients per shift and generate more revenue. Bond Vet's urban model, backed by Warburg Pincus, is consistently cited for a different operational culture than larger roll-up platforms. Its 50-location scale limits the standardization pressures common at 300+ practice networks.

Methodology

This article on private equity in veterinary medicine draws on PE industry databases, veterinary management consulting reports, FTC enforcement records, veterinary industry surveys, and veterinary M&A advisory disclosures current through early 2026. Firm selection reflects PE sponsors and platforms documented in available public sources. Practice counts represent figures reported in the 12-24 months preceding publication. EBITDA multiples reflect Q1 2025 veterinary M&A advisory data and Brakke Consulting industry overviews. Where specific AUM figures for platform entities are not publicly disclosed, the column is omitted rather than estimated. All market statistics reflect the sources noted throughout the article.